Dengue Epitope 10
Description
Recombinant Dengue Multiple Epitopes 10 is genetically designed dengue multiple epitopes epi-10 designed especially for lateral flow product, they are selected from dengue genome. The rapid test prepared by this antigen has over 90% sensitivity and specificity of over 90% to show quick and strong signal for both dengue IgM and IgG.
Product Specs
Product Science Overview
Dengue virus (DENV) is a mosquito-borne flavivirus responsible for significant morbidity and mortality worldwide. It is transmitted primarily by Aedes mosquitoes and has four distinct serotypes: DENV-1, DENV-2, DENV-3, and DENV-4. Infection with one serotype provides lifelong immunity to that serotype but only temporary cross-immunity to the other serotypes. Subsequent infections with different serotypes increase the risk of severe dengue, also known as dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).
The development of an effective dengue vaccine has been challenging due to the complexity of the virus and the need to provide protection against all four serotypes. Multi-epitope vaccines, which incorporate multiple short peptides (epitopes) from different parts of the virus, have emerged as a promising strategy. These vaccines aim to stimulate a broad and robust immune response by targeting multiple viral components.
The Dengue Multiple Epitopes 10 Recombinant is a recombinant protein designed to include multiple epitopes from the dengue virus. This approach leverages the concept of epitope-based vaccines, which focus on specific parts of the virus that are recognized by the immune system. By including multiple epitopes, the vaccine aims to enhance the immune response and provide broader protection against the virus.
The design of the Dengue Multiple Epitopes 10 Recombinant involves identifying and selecting epitopes that are highly conserved across different dengue virus strains and serotypes. These epitopes are then synthesized and combined into a single recombinant protein. The selection process typically involves bioinformatics tools and immunoinformatics approaches to predict the most immunogenic and conserved epitopes.
The recombinant protein is designed to be recognized by the immune system, specifically by B cells and T cells. B cells produce antibodies that can neutralize the virus, while T cells help in clearing infected cells. The inclusion of multiple epitopes ensures that the immune response is directed against several viral components, reducing the likelihood of immune escape by the virus.
- Broad Protection: By targeting multiple epitopes, the vaccine can provide protection against different serotypes and strains of the virus.
- Reduced Risk of Immune Escape: The inclusion of multiple epitopes reduces the chances of the virus mutating to escape the immune response.
- Enhanced Immunogenicity: Multi-epitope vaccines can stimulate both humoral (antibody-mediated) and cellular (T cell-mediated) immune responses.
- Safety: Recombinant proteins are generally considered safe as they do not contain live virus, reducing the risk of vaccine-induced disease.
While multi-epitope vaccines hold great promise, there are several challenges that need to be addressed:
- Epitope Selection: Identifying the most effective epitopes that can provide broad and long-lasting protection is crucial.
- Immune Response: Ensuring that the immune response is balanced and does not lead to antibody-dependent enhancement (ADE), a phenomenon where non-neutralizing antibodies facilitate viral entry into cells.
- Manufacturing: Producing recombinant proteins at scale and ensuring their stability and efficacy.
Future research is focused on optimizing epitope selection, improving vaccine formulations, and conducting clinical trials to evaluate the safety and efficacy of these vaccines in diverse populations.
